Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.73 |
| ▸ | CA1 | P00915 | 4/20 | 0.73 |
| ▸ | CA2 | P00918 | 4/20 | 0.73 |
| ▸ | CA7 | P43166 | 4/20 | 0.73 |
| ▸ | CA9 | Q16790 | 4/20 | 0.73 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.73 |
| ▸ | MAPT | P10636 | 3/20 | 0.73 |
| ▸ | CA4 | P22748 | 3/20 | 0.73 |
| ▸ | CA6 | P23280 | 3/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.73 |
| ▸ | CA3 | P07451 | 2/20 | 0.73 |
| ▸ | CA5A | P35218 | 2/20 | 0.73 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | TP53 | P04637 | 1/20 | 0.73 |
| ▸ | SELL | P14151 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gallic Acid SCHEMBL15012 | 0.85 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL4918056 | 0.85 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL29484566 | 0.85 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL678990 | 0.85 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL8088102 | 0.85 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL1845406 | 0.85 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL30375631 | 0.85 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL1334688 | 0.82 | CA12 (0.94) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL135340 | 0.82 | CA12 (0.94) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL9678849 | 0.82 | CA12 (0.94) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2874664-B1 | COMPOSITION FOR THERAPEUTIC USE, INCLUDING AN ORGANIC LIPID PHASE AND A RARE-EARTH RADIOISOTOPE COMPLEX | CENTRE EUGENE MARQUIS (FR) | 2019-06-19 | — | — | EP | claimed |
| US-9579409-B2 | Composition for therapeutic use, including an organic lipid phase and a rare-earth radioisotope complex | CENTRE EUGENE MARQUIS (FR) | 2017-02-28 | — | — | US | claimed |
| US-20150202334-A1 | COMPOSITION FOR THERAPEUTIC USE, INCLUDING AN ORGANIC LIPID PHASE AND A RARE-EARTH RADIOISOTOPE COMPLEX | ECOLE NATIONALE SUPERIEURE DE CHIMIE (FR) | 2015-07-23 | — | — | US | claimed |
| EP-1808169-B1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | PROTEOTECH INC (US) | 2012-05-30 | — | — | EP | claimed |
| JP-4370072-B2 | — | — | 2009-11-25 | — | — | JP | claimed |
| US-20070191330-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | PROTEOTECH, INC. | 2007-08-16 | — | — | US | claimed |
| EP-1808169-A2 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | Proteotech Inc. (US) | 2007-07-18 | — | — | EP | claimed |
| US-20040152760-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | PROTAMED, INC. | 2004-08-05 | — | — | US | claimed |
| JP-2003532634-A | — | — | 2003-11-05 | — | — | JP | claimed |
| EP-1244435-A2 | POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND $g(a)-SYNUCLEIN FIBRIL DISEASES | Proteotech Inc. (US) | 2002-10-02 | — | — | EP | claimed |
| US-20010047032-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | PROTAMED, INC. | 2001-11-29 | — | — | US | claimed |
| WO-2001049281-A2 | POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND α-SYNUCLEIN FIBRIL DISEASES | PROTEOTECH, INC. (US) | 2001-07-12 | — | — | WO | claimed |
| EP-4735568-A1 | BIODEGRADABLE CHELATING AGENTS AND METHODS FOR FABRIC CARE | The Procter & Gamble Company (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735567-A1 | BIODEGRADABLE CHELATING AGENTS AND METHODS FOR FABRIC CARE | The Procter & Gamble Company (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20250011686-A1 | BIODEGRADABLE CHELATING AGENTS AND METHODS FOR FABRIC CARE | THE PROCTER & GAMBLE COMPANY | 2025-01-09 | — | — | US | disclosed |
| US-20250011687-A1 | BIODEGRADABLE CHELATING AGENTS AND METHODS FOR FABRIC CARE | THE PROCTER & GAMBLE COMPANY | 2025-01-09 | — | — | US | disclosed |
| WO-2001049281-A2 | POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND α-SYNUCLEIN FIBRIL DISEASES | PROTEOTECH, INC. (US) | 2001-07-12 | — | — | WO | disclosed |
| US-5990160-A | Use of tropolone derivatives as inhibitors of the enzyme inositol monophosphatase | GRUPPO LEPETIT, SPA (IT) | 1999-11-23 | — | — | US | disclosed |
| EP-0828483-A1 | USE OF TROPOLONE DERIVATIVES AS INHIBITORS OF THE ENZYME INOSITOL MONOPHOSPHATASE | GRUPPO LEPETIT S.p.A. (IT) | 1998-03-18 | — | — | EP | disclosed |
| WO-1996037197-A1 | USE OF TROPOLONE DERIVATIVES AS INHIBITORS OF THE ENZYME INOSITOL MONOPHOSPHATASE | GRUPPO LEPETIT S.P.A. (IT) | 1996-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191330-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | SNCA, PARK7, HTT | CA12 4851/4885CA1 4847/4885CA2 4873/4885 |
| US-20010047032-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | SNCA, PARK7, HTT | CA12 4845/4885CA1 4840/4885CA2 4874/4885 |
| US-20040152760-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | SNCA, PARK7, HTT | CA12 4845/4885CA1 4840/4885CA2 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.